An Adiponectin Receptor Agonist Reduces Type 2 Diabetic Periodontitis

Area of Science:

• Biomedical Science
• Endocrinology
• Periodontology

Background:

• Type 2 diabetes (T2D) significantly increases periodontitis prevalence and severity.
• Hyperglycemia in T2D impairs bone cell function, exacerbating alveolar bone loss.
• Effective treatments are crucial for managing T2D-associated periodontitis and preserving teeth.

Purpose of the Study:

• To investigate the efficacy of AdipoRon (APR), an adiponectin receptor agonist, in treating experimental periodontitis in diabetic animal models.
• To elucidate the molecular mechanisms underlying APR's effects on bone cells and inflammation in the context of T2D-associated periodontitis.

Main Methods:

• Administration of APR to diet-induced obesity (DIO) diabetic mice with experimental periodontitis.
• In vitro studies to assess APR's effects on osteoclast differentiation.
• Evaluation of inflammatory markers (CCL2, IL-6) and bone regeneration markers (SDF-1) in gingival tissues and bone marrow.
• Treatment of periodontitis in adiponectin (APN) knockout mice to confirm APR's mechanism of action.

Main Results:

• APR significantly reduced osteoclast numbers and alveolar bone loss in diabetic mice.
• APR inhibited osteoclast differentiation in vitro and decreased proinflammatory molecules (CCL2, IL-6) in vivo.
• APR enhanced osteogenic differentiation and promoted alveolar bone regeneration by modulating SDF-1.
• APR's therapeutic effects were observed even in APN knockout mice, indicating activation of endogenous receptors.

Conclusions:

• AdipoRon (APR) demonstrates a multipronged therapeutic potential for T2D-associated periodontitis.
• APR effectively mitigates bone loss and inflammation while promoting alveolar bone regeneration.
• APR represents a promising candidate for developing novel treatments targeting the complex interplay between diabetes and periodontitis.